All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec006}
============

In light of the current global problem of increasing drug resistance, the importance of using antibiotics appropriately is now widely recognized \[[@pone.0235059.ref001]\]. It is also crucial to monitor trends in antimicrobial resistance at the facility or local level to support effective antibiotic selection in empirical treatments, infection control interventions, and antimicrobial resistance containment strategies. Therefore, many medical institutions collect antimicrobial susceptibility test data conducted at their facilities to calculate susceptibility rates and prepare cumulative antibiograms \[[@pone.0235059.ref002]\].

Guidelines have been issued by the Clinical and Laboratory Standards Institute (CLSI) for the preparation of such antibiograms \[[@pone.0235059.ref003]\]. These guidelines set out several recommendations including updating antibiogram data at least once per year, analyzing a minimum of 30 isolates per species, and using only the first isolate when there are repeat or multiple isolates from a patient. However, as compliance to these guidelines requires a significant amount of time and effort, many facilities use dedicated computer software to generate antibiograms \[[@pone.0235059.ref004]\].

While there have been several research studies on how the proposed conditions in the CLSI guidelines affect the calculated susceptibility rates in antibiograms \[[@pone.0235059.ref005], [@pone.0235059.ref006]\], no similar studies have been carried out in Japan.

Sakai City Medical Center is a regional core hospital with facilities for tertiary emergency medical care; there are 480 beds for general clinical care and 7 isolated units for patients with infectious diseases. On July 1 2015, the hospital relocated to a new location approximately 3.5 km away from its original location. The new location is part of a different primary medical care area.

In this study, we evaluated the impact on antimicrobial susceptibility rates when various setpoints for data collection period and duplicate isolate removal period were used during the preparation of cumulative antibiograms. Antimicrobial susceptibility test results, both prior to and after relocation of the Sakai City Medical Center to its new location were also compared.

Materials and methods {#sec007}
=====================

Ethics statement {#sec008}
----------------

This study was approved by the institutional review board of the Sakai City Medical Center (approval number: H30-119). All data was strictly protected after connectable anonymization, and there was no possibility of personal identification in the analyzing process.

Target bacteria, survey period, antimicrobial agents, and determination of susceptibility rates {#sec009}
-----------------------------------------------------------------------------------------------

Gram-negative bacteria can cause many types of infection, including pneumonia, bloodstream infections, wound or surgical site infections, and meningitis; also, Gram-negative bacteria are becoming increasingly resistant to multiple drugs. Hence, among Gram-negative bacteria, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, and *Escherichia coli*, which are frequently isolated, were chosen as the target species.

The survey period was five and a half years, spanning July 2013 to December 2018. All isolates collected at the Sakai City Medical Center Clinical Laboratory during this survey period were subjected to antimicrobial susceptibility tests and the resulting data was analyzed.

The target antimicrobial agents for drug susceptibility tests were penicillins, cephalosporins, carbapenems, monobactams, aminoglycosides, tetracyclines, fluoroquinolones, polymyxins, and others in routine use at the Sakai City Medical Center. [Table 1](#pone.0235059.t001){ref-type="table"} shows target antimicrobial agents by class and their respective abbreviations.

10.1371/journal.pone.0235059.t001

###### Target antimicrobial agents.
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  -------------------------- ---------- -------------------- ------------------------------- ------
  **Penicillins** ^**\***^              **Carbapenems \***                                   
  ampicillin                 ABPC                            doripenem                       DRPM
  ampicillin/sulbactam       ABPC/SBT   imipenem             IPM                             
  piperacillin               PIPC                            meropenem                       MEPM
  piperacillin/tazobactam    PIPC/TAZ                        **Aminoglycosides**             
  **Cephalosporins \***                 amikacin             AMK                             
  ceftazidime                CAZ                             gentamicin                      GM
  cefaclor                   CCL                             tobramycin                      TOB
  cefazolin                  CEZ                             **Tetracyclines**               
  cefepime                   CFPM                            minocycline                     MINO
  cefcapene pivoxil          CFPN                            **Fluoroquinolones**            
  cefmetazole                CMZ                             ciprofloxacin                   CPFX
  cefoperazone/sulbactam     CPZ/SBT                         levofloxacin                    LVFX
  cefotiam                   CTM                             **Polymyxins**                  
  ceftriaxone                CTRX                            colistin                        CL
  cefotaxime                 CTX                             **Others**                      
  cefozopran                 CZOP                            fosfomycin                      FOM
  flomoxef                   FMOX                            sulfamethoxazole/trimethoprim   ST
  **Monobactams \***                                                                         
  aztreonam                  AZT                             \* β-lactam antibiotics         
  -------------------------- ---------- -------------------- ------------------------------- ------

The MIC values from the antimicrobial susceptibility tests were classified as susceptible (S), intermediate (I), or resistant (R), according to the CLSI criteria (M100-S26) \[[@pone.0235059.ref007]\].

Data {#sec010}
----

### Calculation of susceptibility rates {#sec011}

To calculate the susceptibility rates, we used software that we had specifically developed for creating antibiograms, Chans ([Ch]{.ul}arts and [An]{.ul}tibiogram Making [S]{.ul}ystem). Chans is capable of creating antibiograms by setting various conditions such as the specified bacterial species, the antimicrobial agents, and the removal period of duplicate isolates, the data collection period, and the data collection interval \[[@pone.0235059.ref008]\].

In this study the S, I, and R results were uploaded into the Chans system, and the conditions such as the duplicate isolate removal period, the data collection period, and the data collection time were set. The susceptibility rates were then calculated using the following equation: $$Susceptibility\ rate = \frac{no.of\ \mathbf{S}\ isolates}{no.of\ \mathbf{S}\ isolates + no.of\ \mathbf{I}\ isolates + no.of\ \mathbf{R}\ isolates}$$

### Data collection timing and period {#sec012}

For the annual susceptibility rates, cumulative data was calculated in December, whilst this was done in June and December for the bi-annual analyses. The data collection period was defined as the last six months or one year, including the aggregate month.

### Handling of duplicate isolates {#sec013}

As it is possible that isolates from the same patient among long-term in-patients may undergo multiple antimicrobial susceptibility tests during the study period, the CLSI guidelines recommend that only the first isolate is used for analysis per patient per reporting period for a particular antimicrobial agent to prevent results from being affected by duplicate isolates. While there are various ideas on how to deal with duplicate isolates \[[@pone.0235059.ref003], [@pone.0235059.ref005], [@pone.0235059.ref006]\], there has been no unified agreement on the removal period of duplicate isolates \[[@pone.0235059.ref005], [@pone.0235059.ref006]\].

In this study, the duplicate isolate removal periods were set at 365 days, 180 days, and 30 days and the data was collected, respectively.

### Number of patients targeted before and after hospital relocation {#sec014}

With a duplicate isolate removal period of 30 days, the target patients for the last 6 months were analyzed every 6 months. After July 2015, when the hospital was relocated, patients on whom a susceptibility test had been performed at its previous site were identified by their patient IDs, and the proportion that they accounted for out of all the target patients was calculated.

### Statistical analysis {#sec015}

Data were analyzed using R software. The chi-square test was used to assess for associations between susceptibility rate and the duplicate isolate removal periods. Differences in sensibility rates between the long and short data collection periods were also tested using the chi-square test.

Results {#sec016}
=======

Duplicate isolate removal period {#sec017}
--------------------------------

### Influence on number of excluded isolates {#sec018}

For each bacterial species, aggregate data was compiled and analyzed at different duplicate isolate removal periods (30 days, 180 days, and 365 days) and was compared with when all the isolates were used. This data was compared annually. [Table 2](#pone.0235059.t002){ref-type="table"} shows the annual comparisons between the numbers of isolates, the number of excluded isolates, and their proportions at the specified duplicate isolate removal periods for each bacterial species.

10.1371/journal.pone.0235059.t002

###### Effect of duplicate removal period on the number of excluded isolates.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year           Duplicate isolate\   Number of excluded isolates\               Percentage of excluded isolates (%)                                                
                 removal period       / Number of isolates                                                                                                          
  -------------- -------------------- ------------------------------ ----- ----- ------------------------------------- ----- ----- ----- ----- ------ ------ ------ ------
  2014           365 days             157                            /     218   159                                   /     444   50    /     216    41.9   26.4   18.8

  180 days       151                  /                              224   157   /                                     446   50    /     216   40.3   26.0   18.8   

  30 days        109                  /                              266   136   /                                     467   38    /     228   29.1   22.6   14.3   

  all isolates   375                  603                            266   \-    \-                                    \-                                           

  2015           365 days             180                            /     241   251                                   /     641   66    /     219    42.8   28.1   23.2

  180 days       173                  /                              248   241   /                                     651   65    /     220   41.1   27.0   22.8   

  30 days        139                  /                              282   194   /                                     698   53    /     232   33.0   21.7   18.6   

  all isolates   421                  892                            285   \-    \-                                    \-                                           

  2016           365 days             177                            /     264   319                                   /     805   79    /     291    40.1   28.4   21.4

  180 days       171                  /                              270   307   /                                     817   76    /     294   38.8   27.3   20.5   

  30 days        132                  /                              309   241   /                                     883   65    /     305   29.9   21.4   17.6   

  all isolates   441                  1124                           370   \-    \-                                    \-                                           

  2017           365 days             200                            /     306   323                                   /     751   114   /     328    39.5   30.1   25.8

  180 days       194                  /                              312   314   /                                     760   112   /     330   38.3   29.2   25.3   

  30 days        159                  /                              347   261   /                                     813   97    /     345   31.4   24.3   21.9   

  all isolates   506                  1074                           442   \-    \-                                    \-                                           

  2018           365 days             233                            /     278   269                                   /     781   121   /     341    45.6   25.6   26.2

  180 days       231                  /                              280   261   /                                     789   120   /     342   45.2   24.9   26.0   

  30 days        191                  /                              320   214   /                                     836   98    /     364   37.4   20.4   21.2   

  all isolates   511                  1050                           462   \-    \-                                    \-                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For all bacterial species, the proportion of excluded isolates increased as the duplicate isolate removal period increased, with a concomitant reduction in the number of target isolates. The mean proportion and (standard deviation) of excluded isolates when the duplicate isolate removal periods were set at 365 days, 180 days, and 30 days were 42.0 (2.2), 40.7 (2.4), and 32.2 (2.9) for *P*. *aeruginosa*; 27.7 (1.6), 26.9 (1.5), and 22.1 (1.3) for *E*. *coli*; and 23.1 (2.8), 22.7 (2.7), and 18.7 (2.7) for *K*. *pneumoniae*, with no significant annual variations noted.

### Influence on susceptibility rates {#sec019}

Tables [3](#pone.0235059.t003){ref-type="table"}--[5](#pone.0235059.t005){ref-type="table"} show the antimicrobial agent susceptibility rates for each bacterial species when the duplicate isolate removal periods were 365 days, 180 days, and 30 days, and when all the isolates were used. All susceptibility rates when the duplicate isolate removal periods were set were compared against when all strains were used. When there were significant differences, these were indicated by asterisks in the tables.

10.1371/journal.pone.0235059.t003

###### Effect of duplicate isolate removal period on susceptible rates of *P*. *aeruginosa*.
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                 Susceptible rate (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  -------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ------ ------ ------ --------------------------------------------- --------------------------------------------- ------ -----
  2014           365 days                                      88.5[\*\*](#t003fn003){ref-type="table-fn"}   93.1[\*\*](#t003fn003){ref-type="table-fn"}   91.3[\*\*](#t003fn003){ref-type="table-fn"}   90.4[\*\*](#t003fn003){ref-type="table-fn"}   89.9[\*](#t003fn002){ref-type="table-fn"}     94.0                                          95.4[\*\*](#t003fn003){ref-type="table-fn"}   88.1[\*](#t003fn002){ref-type="table-fn"}     92.2[\*](#t003fn002){ref-type="table-fn"}     84.9[\*](#t003fn002){ref-type="table-fn"}     94.0   79.4   95.4   92.2                                          91.3[\*\*](#t003fn003){ref-type="table-fn"}   98.6   9.2
  180 days       87.9[\*\*](#t003fn003){ref-type="table-fn"}   92.9[\*\*](#t003fn003){ref-type="table-fn"}   90.6[\*\*](#t003fn003){ref-type="table-fn"}   89.7[\*\*](#t003fn003){ref-type="table-fn"}   89.3[\*](#t003fn002){ref-type="table-fn"}     94.6                                          95.1[\*\*](#t003fn003){ref-type="table-fn"}   87.9[\*](#t003fn002){ref-type="table-fn"}     91.0[\*](#t003fn002){ref-type="table-fn"}     84.4[\*](#t003fn002){ref-type="table-fn"}     94.2                                          78.6   95.5   91.0   90.6[\*\*](#t003fn003){ref-type="table-fn"}   98.7                                          8.9    
  30 days        85.7                                          90.2                                          87.0                                          86.8                                          86.5                                          91.7                                          92.9                                          86.1[\*\*](#t003fn003){ref-type="table-fn"}   89.8                                          81.2[\*\*](#t003fn003){ref-type="table-fn"}   94.4                                          77.1   95.1   91.4   88.3                                          98.5                                          9.0    
  all isolates   80.8                                          86.4                                          84.5                                          82.4                                          80.5                                          90.1                                          89.1                                          79.2                                          84.3                                          74.1                                          94.9                                          76.8   96.0   88.8   84.3                                          98.1                                          9.6    
  2015           365 days                                      95.4[\*](#t003fn002){ref-type="table-fn"}     97.5[\*](#t003fn002){ref-type="table-fn"}     97.9[\*](#t003fn002){ref-type="table-fn"}     95.0[\*\*](#t003fn003){ref-type="table-fn"}   95.0[\*\*](#t003fn003){ref-type="table-fn"}   98.3[\*](#t003fn002){ref-type="table-fn"}     97.9[\*](#t003fn002){ref-type="table-fn"}     88.4                                          95.0[\*\*](#t003fn003){ref-type="table-fn"}   90.5                                          97.5   86.7   99.2   94.6                                          93.8                                          97.9   8.7
  180 days       95.6[\*](#t003fn002){ref-type="table-fn"}     97.6[\*](#t003fn002){ref-type="table-fn"}     97.0[\*](#t003fn002){ref-type="table-fn"}     95.2[\*\*](#t003fn003){ref-type="table-fn"}   95.2[\*\*](#t003fn003){ref-type="table-fn"}   98.4[\*](#t003fn002){ref-type="table-fn"}     97.0[\*](#t003fn002){ref-type="table-fn"}     88.3                                          95.2[\*\*](#t003fn003){ref-type="table-fn"}   90.7                                          97.6                                          87.1   99.2   94.8   93.5                                          97.0                                          8.5    
  30 days        92.9                                          95.0                                          94.7[\*\*](#t003fn003){ref-type="table-fn"}   92.2                                          91.5                                          95.7                                          95.4                                          85.8                                          92.2                                          87.6                                          97.2                                          86.9   98.6   92.9   91.5                                          98.2                                          8.2    
  all isolates   88.6                                          90.0                                          90.0                                          89.1                                          89.1                                          92.9                                          92.6                                          83.6                                          89.5                                          85.5                                          97.1                                          85.5   98.3   90.0   90.0                                          98.3                                          7.1    
  2016           365 days                                      97.7[\*](#t003fn002){ref-type="table-fn"}     99.2[\*](#t003fn002){ref-type="table-fn"}     98.5[\*](#t003fn002){ref-type="table-fn"}     96.0[\*](#t003fn002){ref-type="table-fn"}     95.5[\*](#t003fn002){ref-type="table-fn"}     98.9[\*](#t003fn002){ref-type="table-fn"}     97.3[\*\*](#t003fn003){ref-type="table-fn"}   90.2[\*\*](#t003fn003){ref-type="table-fn"}   93.2[\*\*](#t003fn003){ref-type="table-fn"}   90.9[\*\*](#t003fn003){ref-type="table-fn"}   96.6   90.2   97.3   93.9                                          93.9                                          98.5   7.2
  180 days       96.7[\*](#t003fn002){ref-type="table-fn"}     98.9[\*](#t003fn002){ref-type="table-fn"}     98.5[\*](#t003fn002){ref-type="table-fn"}     96.3[\*](#t003fn002){ref-type="table-fn"}     95.2[\*](#t003fn002){ref-type="table-fn"}     98.9[\*](#t003fn002){ref-type="table-fn"}     97.0                                          90.0[\*\*](#t003fn003){ref-type="table-fn"}   92.0[\*\*](#t003fn003){ref-type="table-fn"}   90.4                                          96.7                                          89.6   97.4   93.3   93.3                                          98.5                                          7.0    
  30 days        92.6                                          95.5                                          94.5                                          92.2                                          91.3                                          96.4                                          94.8                                          88.0                                          90.9                                          86.7                                          96.1                                          87.7   97.1   91.3   90.9                                          98.4                                          6.5    
  all isolates   89.3                                          92.1                                          91.6                                          90.5                                          88.4                                          94.3                                          93.4                                          84.1                                          87.0                                          85.3                                          96.8                                          89.3   97.7   91.4   90.9                                          98.9                                          5.7    
  2017           365 days                                      93.8[\*\*](#t003fn003){ref-type="table-fn"}   95.1[\*\*](#t003fn003){ref-type="table-fn"}   94.8[\*\*](#t003fn003){ref-type="table-fn"}   95.1[\*\*](#t003fn003){ref-type="table-fn"}   93.1[\*\*](#t003fn003){ref-type="table-fn"}   97.4[\*\*](#t003fn003){ref-type="table-fn"}   96.7                                          93.1                                          94.8                                          89.2[\*\*](#t003fn003){ref-type="table-fn"}   98.4   92.5   99.0   94.1                                          95.4                                          98.7   5.9
  180 days       93.6[\*\*](#t003fn003){ref-type="table-fn"}   95.2[\*\*](#t003fn003){ref-type="table-fn"}   94.9[\*\*](#t003fn003){ref-type="table-fn"}   94.9[\*\*](#t003fn003){ref-type="table-fn"}   92.9[\*\*](#t003fn003){ref-type="table-fn"}   97.4[\*\*](#t003fn003){ref-type="table-fn"}   96.5                                          92.9                                          94.6                                          89.1[\*\*](#t003fn003){ref-type="table-fn"}   98.4                                          92.3   99.0   93.9   95.2                                          98.7                                          5.8    
  30 days        92.5[\*\*](#t003fn003){ref-type="table-fn"}   94.5[\*\*](#t003fn003){ref-type="table-fn"}   94.2                                          93.9                                          91.6                                          96.5                                          95.7                                          92.2                                          93.7                                          87.9                                          98.6                                          92.2   99.1   93.9   94.5                                          98.6                                          6.3    
  all isolates   88.1                                          90.1                                          90.7                                          90.3                                          87.7                                          94.1                                          94.3                                          90.7                                          92.3                                          83.0                                          98.6                                          91.9   99.2   95.5   95.7                                          98.2                                          7.7    
  2018           365 days                                      95.3[\*](#t003fn002){ref-type="table-fn"}     95.7[\*](#t003fn002){ref-type="table-fn"}     96.4[\*](#t003fn002){ref-type="table-fn"}     94.2[\*\*](#t003fn003){ref-type="table-fn"}   94.0[\*\*](#t003fn003){ref-type="table-fn"}   97.5[\*\*](#t003fn003){ref-type="table-fn"}   98.2[\*](#t003fn002){ref-type="table-fn"}     91.0[\*](#t003fn002){ref-type="table-fn"}     97.1[\*](#t003fn002){ref-type="table-fn"}     88.5                                          98.6   85.6   99.3   94.2                                          93.2                                          98.9   6.8
  180 days       95.4[\*](#t003fn002){ref-type="table-fn"}     95.7[\*](#t003fn002){ref-type="table-fn"}     96.1[\*](#t003fn002){ref-type="table-fn"}     94.3[\*\*](#t003fn003){ref-type="table-fn"}   95.0[\*\*](#t003fn003){ref-type="table-fn"}   97.5[\*\*](#t003fn003){ref-type="table-fn"}   98.2[\*](#t003fn002){ref-type="table-fn"}     90.7[\*](#t003fn002){ref-type="table-fn"}     97.1[\*](#t003fn002){ref-type="table-fn"}     88.2                                          98.6                                          85.7   99.3   93.9   92.9                                          98.9                                          6.8    
  30 days        93.4                                          93.8                                          94.7[\*\*](#t003fn003){ref-type="table-fn"}   92.8                                          93.1                                          96.3                                          97.2[\*\*](#t003fn003){ref-type="table-fn"}   89.1[\*\*](#t003fn003){ref-type="table-fn"}   95.0[\*](#t003fn002){ref-type="table-fn"}     85.9                                          98.8                                          85.9   99.4   93.8   92.5                                          98.8                                          6.3    
  all isolates   89.6                                          90.0                                          90.4                                          89.2                                          90.0                                          93.3                                          93.2                                          83.8                                          89.4                                          83.4                                          98.6                                          85.7   99.6   93.5   92.0                                          98.6                                          9.4    

365 days, 180 days, 30 days vs all isolates:

\* *P*\<0.01

\*\* *P*\<0.05

10.1371/journal.pone.0235059.t004

###### Effect of duplicate isolate removal period on susceptible rates of *E*. *coli*.
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                 Susceptible rate (%)                                                                                                                                                                       
  -------------- ---------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------- ------- ------- ------ ------ ------ ------ ------ ------ ------
  2014           365 days               59.2   64.2   63.3   98.2   86.3   79.5   78.6   87.2   86.7   99.1   93.0   85.1   85.4   85.1   98.6    100.0   100.0   86.3   99.5   91.2   91.7   72.0   86.7   82.4
  180 days       59.2                   64.1   63.2   98.2   86.1   79.4   78.5   86.0   86.6   99.1   93.0   84.0   85.2   84.0   98.7   100.0   100.0   86.1    99.6   91.3   91.5   72.6   86.8   82.3   
  30 days        57.8                   62.7   61.9   98.1   85.0   78.2   77.1   86.5   85.8   98.9   92.5   83.9   84.2   83.9   98.1   100.0   100.0   85.0    99.6   91.2   91.4   71.7   86.7   82.0   
  all isolates   58.0                   62.7   61.7   97.5   85.4   77.9   77.4   86.6   85.0   99.2   91.2   84.2   84.6   84.4   98.3   100.0   100.0   85.4    99.7   91.0   91.9   72.1   87.4   81.6   
  2015           365 days               54.1   64.4   60.2   98.4   80.5   73.9   73.6   81.1   80.3   99.1   93.8   79.7   79.9   79.9   98.6    100.0   100.0   79.7   99.7   89.4   90.5   68.5   87.4   79.4
  180 days       53.9                   64.4   59.9   98.5   80.2   73.7   73.4   80.8   80.1   99.1   93.7   79.4   79.6   79.6   98.6   100.0   100.0   79.4    99.7   89.1   90.5   68.0   87.4   79.1   
  30 days        52.4                   63.2   58.6   98.4   78.9   72.3   72.5   79.5   78.6   99.1   92.6   78.2   78.4   78.4   98.6   100.0   100.0   78.2    99.7   88.0   89.3   66.0   87.5   77.8   
  all isolates   52.7                   63.0   58.4   98.3   78.6   71.0   72.4   79.4   78.2   98.0   92.2   77.8   78.1   78.1   98.3   100.0   100.0   78.0    99.7   89.0   89.2   64.6   88.6   77.8   
  2016           365 days               51.9   60.9   58.4   97.3   78.4   69.9   70.2   79.4   77.8   98.8   91.3   77.5   77.9   77.6   98.3    99.9    99.8    78.6   99.6   90.5   89.2   66.0   91.1   79.4
  180 days       51.7                   60.0   58.1   97.3   78.0   69.5   69.9   79.1   77.4   98.8   91.2   77.1   77.5   77.2   98.3   99.9    99.8    78.1    99.6   90.5   89.1   65.8   91.2   79.4   
  30 days        50.4                   60.6   56.8   97.3   76.8   68.3   68.6   77.0   76.0   98.8   90.8   75.9   76.3   75.0   98.2   99.9    99.8    76.9    99.7   90.6   88.4   64.6   90.8   78.4   
  all isolates   50.7                   61.2   56.8   96.4   75.6   67.5   67.9   76.6   74.4   98.7   90.5   74.7   75.1   74.9   98.4   99.9    99.8    75.7    99.7   90.9   88.6   63.9   91.2   78.8   
  2017           365 days               55.3   64.3   60.7   98.9   83.1   76.8   77.5   84.3   83.3   99.2   94.7   82.8   83.1   82.7   98.9    100.0   100.0   83.4   99.9   92.4   93.5   69.9   90.9   83.2
  180 days       54.9                   63.9   60.3   98.9   82.9   76.7   77.2   84.1   83.0   99.2   94.6   82.6   82.9   82.5   98.9   100.0   100.0   83.2    99.9   92.2   93.4   69.5   90.8   82.9   
  30 days        53.6                   63.1   58.8   98.9   81.1   75.2   75.8   82.3   81.1   99.3   93.7   80.8   81.1   80.7   99.0   100.0   100.0   81.4    99.9   92.6   93.1   67.5   90.5   81.9   
  all isolates   52.0                   61.5   56.9   98.7   79.5   73.8   74.6   80.7   79.4   99.3   93.5   79.3   79.6   79.2   99.2   100.0   100.0   79.9    99.9   92.2   92.7   66.4   91.5   81.2   
  2018           365 days               53.8   63.4   58.3   98.2   80.9   73.5   73.5   81.9   81.2   98.7   93.0   80.0   80.3   80.0   98.2    99.9    99.9    80.8   99.7   90.3   93.5   66.2   92.1   78.9
  180 days       53.6                   63.1   58.2   98.1   80.0   73.4   73.4   82.0   81.2   98.7   93.9   80.1   80.4   80.1   98.2   99.9    99.9    80.9    99.7   90.4   93.5   66.2   92.1   78.8   
  30 days        52.9                   62.6   57.8   97.0   80.9   72.7   72.7   81.8   81.0   98.6   93.7   79.8   80.1   79.8   98.1   99.9    99.9    80.6    99.8   90.7   93.4   65.7   91.9   78.6   
  all isolates   51.5                   61.7   56.2   98.2   79.0   70.8   70.8   80.2   79.1   98.6   93.7   78.0   78.4   78.1   97.9   99.9    99.8    78.8    99.8   90.8   93.0   65.2   92.0   77.7   

365 days, 180 days, 30 days vs all isolates: \* *P*\<0.01, \*\* *P*\<0.05

10.1371/journal.pone.0235059.t005

###### Effect of duplicate isolate removal period on susceptible rates of *K. pneumoniae*.

![](pone.0235059.t005){#pone.0235059.t005g}

                 Susceptible rate (%)                                                                                                                                                                           
  -------------- ---------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------- ------- ------ ------ ------ ------ ------- ------- ------- ------- ------- ------ ------ ------ ------ ------
  2014           365 days               0.0    84.7   62.5   98.6   95.8   94.4   93.1   95.8   95.4    99.1    97.7   94.0   95.4   95.4   99.5    100.0   100.0   95.8    100.0   98.1   85.2   98.1   35.2   90.3
  180 days       0.0                    84.7   62.5   98.6   95.8   94.4   93.1   95.8   95.4   99.1    97.7    94.0   95.4   95.4   99.5   100.0   100.0   95.8    100.0   98.1    85.2   98.1   35.2   90.3   
  30 days        0.0                    83.8   61.8   98.2   94.7   93.4   92.1   94.7   94.3   99.1    96.9    93.0   94.3   94.3   99.6   100.0   100.0   94.7    100.0   97.4    84.6   98.2   34.6   89.5   
  all isolates   0.0                    83.8   63.2   98.1   94.4   93.2   92.1   94.4   93.9   99.2    96.6    92.9   94.0   94.0   99.6   100.0   100.0   94.4    100.0   97.0    85.3   98.1   34.2   89.1   
  2015           365 days               0.0    91.8   71.2   98.2   97.7   95.9   95.9   98.2   98.1    100.0   98.6   97.7   97.7   97.7   99.5    100.0   100.0   97.7    100.0   99.1   92.2   99.5   39.7   93.6
  180 days       0.0                    91.8   71.4   98.2   97.7   95.9   95.9   98.2   98.1   100.0   98.6    97.7   97.7   97.7   99.5   100.0   100.0   97.7    100.0   99.1    92.3   99.5   40.0   93.6   
  30 days        0.0                    90.9   71.1   98.3   97.4   95.7   95.7   97.8   97.8   100.0   98.7    97.4   97.4   97.4   99.6   100.0   100.0   97.4    100.0   98.7    91.8   99.6   40.9   93.5   
  all isolates   0.0                    90.5   70.2   97.9   97.2   95.8   95.4   98.2   98.2   100.0   98.2    97.9   97.9   97.9   99.6   100.0   100.0   97.5    100.0   98.9    90.9   98.9   41.4   93.7   
  2016           365 days               0.0    90.4   70.1   99.0   96.9   95.9   95.5   96.9   96.7    99.3    98.6   95.9   96.9   96.6   99.3    99.7    99.7    96.9    100.0   97.9   90.4   98.3   31.3   93.8
  180 days       0.0                    90.1   70.1   99.0   96.9   95.9   95.6   96.9   96.8   99.3    98.6    95.9   96.9   96.6   99.3   99.7    99.7    96.9    100.0   97.6    90.5   98.3   31.3   93.5   
  30 days        0.0                    90.5   70.8   99.0   97.0   96.1   95.7   97.0   96.9   99.3    98.7    96.1   97.0   96.7   99.3   99.7    99.7    97.0    100.0   97.7    90.5   98.4   31.8   93.4   
  all isolates   0.0                    90.0   70.0   98.4   96.5   95.7   95.4   96.5   97.1   98.4    97.8    95.7   96.5   96.2   98.4   99.2    99.2    96.5    100.0   97.8    89.7   98.4   33.2   93.0   
  2017           365 days               0.0    85.1   71.3   98.8   96.6   95.1   95.1   96.6   96.5    99.7    97.9   95.7   96.3   95.7   99.7    100.0   100.0   96.3    100.0   96.3   88.1   98.5   30.2   93.3
  180 days       0.0                    84.8   71.2   98.8   96.7   95.2   95.2   96.7   96.5   99.7    97.9    95.8   96.4   95.8   99.7   100.0   100.0   96.4    100.0   96.4    88.2   98.5   30.3   93.3   
  30 days        0.0                    84.1   70.4   98.8   95.9   94.8   94.5   96.2   96.0   99.4    98.0    95.1   95.9   95.4   99.7   100.0   100.0   95.9    100.0   96.5    87.5   98.6   30.1   93.0   
  all isolates   0.0                    82.4   70.4   98.9   95.7   94.1   93.7   95.7   95.7   99.1    98.0    94.3   95.5   94.8   99.3   100.0   100.0   95.5    100.0   96.4    88.5   98.4   30.3   92.8   
  2018           365 days               0.0    84.5   59.8   98.2   96.2   95.0   94.7   96.8   96.6    99.1    99.4   95.9   96.2   95.9   99.1    99.7    100.0   96.2    100.0   97.9   89.7   97.4   24.3   91.5
  180 days       0.0                    84.2   59.6   98.2   95.9   94.7   94.4   96.5   96.3   99.1    99.4    95.6   95.9   95.6   99.1   99.7    100.0   95.9    100.0   97.7    89.5   97.4   24.6   91.2   
  30 days        0.0                    83.2   59.1   97.8   95.3   94.2   93.7   96.2   95.9   98.9    98.9    95.1   95.3   95.1   98.9   99.7    100.0   95.3    100.0   97.8    89.0   97.3   24.2   90.4   
  all isolates   0.0                    82.7   57.8   98.3   95.5   94.2   93.5   96.3   95.9   98.3    99.1    94.8   95.7   95.0   98.5   99.6    100.0   95.7    100.0   98.1    87.9   97.8   25.1   90.9   

365 days, 180 days, 30 days vs all isolates: \* *P*\<0.01, \*\* *P*\<0.05

The *P*. *aeruginosa* susceptibility rates to β-lactam antibiotics (penicillins, cephalosporins, carbapenems, and monobactams) increased as the duplicate isolate removal period increased. When the duplicate isolate removal periods were 365 days and 180 days, the susceptibility rates for most β-lactam antibiotics were significantly higher compared with when all isolates were used.

By setting different duplicate isolate removal periods and comparing the data to when all the isolates were used, the biggest increase in drug susceptibility rates was observed for AZT in 2014, with values of 74.1% (all isolates) to 84.9% (at 365 days). Susceptibility rates with the smallest increases were observed in 2016 for DRPM, with values of 93.4%--94.8%.

The *P*. *aeruginosa* susceptibility rates to non-β-lactam antibiotics did not show a regular increase or decrease with changes in the duplicate isolate removal periods.

The *E*. *coli* susceptibility rates to all antimicrobial agents did not show a regular increase or decrease with the change in the duplicate isolate removal periods. In addition, there was no significant change in the susceptibility rate due to the duplicate isolate removal periods. However, with CCL alone, the susceptibility rates increased as the duplicate isolate removal periods increased, albeit with only a small change of up to 3%.

The *K*. *pneumoniae* susceptibility rates did not show a regular trend for all antimicrobial agents. There also was no significant change in the susceptibility rate due to the duplicate isolate removal periods. However, in the case of CEZ alone, the susceptibility rates increased as the duplicate isolate removal periods increased, although the change range was as small as 1.5%.

Please refer to the supporting information for detailed data on the difference in susceptibility when all isolates were used and when the duplicate isolate removal period was 365 days, 180 days, and 30 days ([S1 Table](#pone.0235059.s002){ref-type="supplementary-material"}).

In order to compare the variation in susceptibility rate due to the duplicate isolate removal periods among antimicrobial agents, the susceptibility rate change resulting from the duplicate isolate removal periods was aggregated every year and the coefficient of variation was calculated. This is shown in Figs [1](#pone.0235059.g001){ref-type="fig"}--[3](#pone.0235059.g003){ref-type="fig"} for each bacterial species.

![Coefficients of variation of *P*. *aeruginosa* susceptibility rates to each antibacterial drug due to the duplicate isolate removal periods for each year.](pone.0235059.g001){#pone.0235059.g001}

![Coefficients of variation of *E*. *coli* susceptibility rates to each antibacterial drug due to the duplicate isolate removal periods for each year.](pone.0235059.g002){#pone.0235059.g002}

![Coefficients of variation of *K*. *pneumoniae* susceptibility rates to each antibacterial drug due to the duplicate isolate removal periods for each year.](pone.0235059.g003){#pone.0235059.g003}

The coefficients of variation of susceptibility rates of each antimicrobial agent by the duplicate isolate removal periods in *P*. *aeruginosa* were one order of magnitude greater than in *E*. *coli* and *K*. *pneumoniae*. In *P*. *aeruginosa*, the coefficients of variation of susceptibility rates of β-lactam antibiotics were around 0.04, which were larger than those of other antimicrobials, and of aminoglycoside agents and colistin were much smaller (approximately 0.003). The coefficients of variation for fluoroquinolone agents were approximately 0.02, which were about halfway between the two, and the FOM showed larger coefficients of variation than the others.

In *E*. *coli*, the coefficients of variation in the susceptibility rates of each antimicrobial agent depending on the duplicate isolate removal periods were relatively high for β-lactam antibiotics, but most were less than 0.02, which was comparable to the coefficients of variation shown by aminoglycoside agents in *P*. *aeruginosa*. Among β-lactam antibiotics, PIPC/TAZ, CMZ, FMOX, and MEPM had low coefficients of variation of less than 0.005. The aminoglycoside agents AMK and GM also showed low values, whereas the fluoroquinolone LVFX showed relatively high values.

In *K*. *pneumoniae*, the coefficients of variation of the susceptibility rates of each antimicrobial by the duplicate isolate removal periods were generally even lower than those of *E*. *coli*, and many were less than 0.01. CMZ, IPM, MEPM, and AMK showed particularly low values, but these were the antimicrobials that always showed 100% or near 100% susceptibility.

Data collection period {#sec020}
----------------------

Antimicrobial susceptibility rates were stratified every 6 months according to duplicate isolate removal periods and data collection periods of 6 months or 1 year over the course of the study. The *P*. *aeruginosa* susceptibility rates to β-lactam antibiotics, as well as the average values for the five-year study period are shown in [Table 6](#pone.0235059.t006){ref-type="table"}.

10.1371/journal.pone.0235059.t006

###### Effect of the data collection period on *P*. *aeruginosa* susceptibility rates.

![](pone.0235059.t006){#pone.0235059.t006g}

                                                                      Susceptible rate (%)                                                                                                                                     
  -------------- ------------------------------------------- -------- ---------------------- ------------------------------------------- ------ ------ ------ ------ ------ ------------------------------------------- ------ ------
  PIPC           180 days                                    1 year   92.0                   87.9                                        90.5   95.6   97.6   96.7   94.0   93.6                                        95.1   95.4
  6 months       84.7                                        90.2     90.7                   98.7                                        96.2   95.4   92.7   93.5   96.1   94.9                                               
  30 days        1 year                                      89.9     85.7                   87.3                                        92.9   94.8   92.6   92.5   92.5   93.5                                        93.4   
  6 months       82.8                                        87.5     85.6                   97.7[\*](#t006fn002){ref-type="table-fn"}   90.6   92.8   92.2   92.9   93.2   93.8                                               
  all isolates   1 year                                      87.2     80.8                   82.4                                        88.6   92.1   89.3   88.8   88.1   87.8                                        89.6   
  6 months       78.4[\*](#t006fn002){ref-type="table-fn"}   82.8     81.8                   93.2                                        90.3   88.9   88.8   87.6   88.0   91.1                                               
  PIPC/TAZ       180 days                                    1 year   95.0                   92.9                                        94.1   97.6   99.2   98.9   96.2   95.2                                        95.8   95.7
  6 months       89.8                                        94.7     93.8                   100.0                                       98.1   97.7   94.7   95.2   95.3   95.5                                               
  30 days        1 year                                      92.3     90.2                   90.8                                        95.0   97.2   95.5   94.7   94.5   94.7                                        93.8   
  6 months       87.1                                        92.1     88.3                   99.4[\*](#t006fn002){ref-type="table-fn"}   94.0   95.4   94.0   95.1   93.2   94.3                                               
  all isolates   1 year                                      90.3     86.4                   86.9                                        91.0   94.1   92.1   91.3   90.1   89.0                                        90.0   
  6 months       84.2                                        88.2     85.3                   94.8                                        92.9   91.6   90.8   89.5   88.4   91.4                                               
  CAZ            180 days                                    1 year   93.0                   90.6                                        93.7   98.0   99.2   98.5   95.6   94.9                                        96.1   96.1
  6 months       86.7                                        93.2     94.8                   100.0                                       98.1   97.1   94.0   95.2   96.1   96.2                                               
  30 days        1 year                                      89.9     88.0                   89.6                                        94.7   96.5   94.5   93.9   94.2   95.4                                        94.7   
  6 months       84.5                                        90.1     88.3                   98.8[\*](#t006fn002){ref-type="table-fn"}   93.2   94.3   93.4   95.1   94.5   94.9                                               
  all isolates   1 year                                      86.2     84.5                   85.3                                        90.0   93.6   91.6   91.5   90.7   89.4                                        90.4   
  6 months       82.5                                        86.3     84.1                   94.0                                        92.9   90.9   92.1   89.5   89.3   91.4                                               
  CFPM           180 days                                    1 year   92.0                   89.7                                        92.3   95.2   96.0   96.3   95.0   94.9                                        96.5   94.3
  6 months       85.7                                        92.4     91.8                   97.4                                        94.3   96.5   93.4   95.8   94.5   94.3                                               
  30 days        1 year                                      87.1     86.8                   89.2                                        92.2   92.7   92.2   92.8   93.9   95.0                                        92.8   
  6 months       81.9                                        90.1     87.4                   95.3                                        88.9   93.3   92.2   95.6   92.5   93.2                                               
  all isolates   1 year                                      81.8     82.4                   86.4                                        89.1   90.1   90.5   91.1   90.3   89.2                                        89.2   
  6 months       77.8                                        86.3     86.5                   90.8                                        89.0   91.3   90.8   89.8   88.4   90.0                                               
  CPZ/SBT        180 days                                    1 year   91.0                   89.3                                        91.4   95.2   96.4   95.2   93.4   92.9                                        94.0   95.0
  6 months       86.7                                        90.9     90.7                   98.0                                        94.3   94.2   92.7   92.9   94.5   95.5                                               
  30 days        1 year                                      88.3     86.5                   87.7                                        91.5   93.7   91.3   91.1   91.6   93.2                                        93.1   
  6 months       83.6                                        88.2     84.7                   95.9                                        89.7   91.2   91.0   92.3   93.2   93.2                                               
  all isolates   1 year                                      84.7     80.5                   82.4                                        89.1   91.4   88.4   88.4   87.7   88.2                                        90.0   
  6 months       80.1                                        80.9     84.1                   92.4                                        89.6   87.8   89.2   86.5   90.1   90.0                                               
  CZOP           180 days                                    1 year   95.5                   94.6                                        96.4   98.4   98.8   98.9   97.8   97.4                                        98.6   97.5
  6 months       91.8                                        97.0     95.9                   100.0                                       97.2   98.8   96.7   97.6   98.4   96.8                                               
  30 days        1 year                                      91.9     91.7                   93.8                                        95.7   96.5   96.4   96.7   96.5   97.8                                        96.3   
  6 months       87.9                                        94.7     91.9                   98.2                                        93.2   97.4   95.8   97.3   97.3   95.5                                               
  all isolates   1 year                                      90.3     90.1                   90.9                                        92.9   94.1   94.3   95.1   94.1   93.5                                        93.3   
  6 months       87.7                                        92.2     89.4                   95.2                                        92.2   95.5   94.6   93.6   93.4   93.3                                               
  DRPM           180 days                                    1 year   92.9                   95.1                                        95.9   98.0   98.0   97.0   95.9   96.5                                        97.9   98.2
  6 months       92.9                                        96.2     95.9                   99.3                                        96.2   96.5   95.4   97.6   98.4   98.1                                               
  30 days        1 year                                      89.7     92.9                   93.8                                        95.4   95.8   94.8   95.3   95.7   97.2                                        97.2   
  6 months       89.7                                        94.7     91.9                   97.7                                        92.3   95.9   94.6   96.7   97.9   96.6                                               
  all isolates   1 year                                      90.1     89.1                   88.5                                        92.6   92.6   93.4   94.9   94.3   95.3                                        93.2   
  6 months       90.1                                        88.2     88.8                   95.2                                        88.3   96.2   93.3   95.1   95.5   91.1                                               
  IPM            180 days                                    1 year   90.5                   87.9                                        88.7   88.3   89.7   90.0   89.6   92.9                                        94.7   90.7
  6 months       85.7                                        89.4     87.6                   88.8                                        90.6   88.4   91.4   94.6   95.3   86.0                                               
  30 days        1 year                                      85.9     86.1                   85.0                                        85.8   88.2   88.0   89.2   92.2   93.8                                        89.1   
  6 months       83.6                                        86.8     82.0                   88.3                                        87.2   87.6   91.0   93.4   94.5   84.7                                               
  all isolates   1 year                                      81.6     79.2                   80.5                                        83.6   84.0   84.1   87.3   90.7   91.7                                        83.8   
  6 months       77.8                                        80.4     80.6                   85.7                                        81.2   85.7   89.2   92.1   91.3   77.0[\*](#t006fn002){ref-type="table-fn"}          
  MEPM           180 days                                    1 year   93.5                   92.0                                        94.6   95.2   94.8   93.0   92.8   94.6                                        96.5   97.1
  6 months       88.8                                        93.9     93.8                   96.1                                        92.5   92.5   93.4   95.8   97.7   94.9                                               
  30 days        1 year                                      90.3     89.8                   91.5                                        92.2   92.7   90.9   92.2   93.7   95.4                                        95.0   
  6 months       86.2                                        92.1     89.2                   94.2                                        88.9   91.8   92.8   94.5   96.6   93.2                                               
  all isolates   1 year                                      89.0     84.3                   85.3                                        89.5   88.9   88.0   90.3   92.3   92.9                                        89.4   
  6 months       84.8                                        83.8     87.1                   91.2                                        85.1   89.5   91.3   93.2   92.6   86.6                                               
  AZT            180 days                                    1 year   84.1                   84.4                                        86.5   90.7   94.0   90.4   88.7   89.1                                        87.0   88.2
  6 months       78.6                                        88.6     83.5                   95.4                                        90.6   89.0   88.7   88.1   83.6   91.1                                               
  30 days        1 year                                      79.8     81.2                   83.1                                        87.6   90.2   86.7   86.7   87.9   86.1                                        85.9   
  6 months       75.0                                        85.5     79.3                   93.0                                        86.3   86.1   87.3   88.0   82.2   88.6                                               
  all isolates   1 year                                      71.2     74.1                   78.9                                        85.5   87.9   85.3   84.4   83.0   82.3                                        83.4   
  6 months       70.2                                        77.5     80.6                   88.8                                        86.4   84.7   84.2   82.0   82.6   84.0                                               

6 month vs 1 year:

\* *P*\<0.05

The susceptibility of *P*. *aeruginosa* to β-lactam antibiotics increases or decreases depending on the data collection period, and no regularity was found. In terms of variation in the data collection periods, the highest observed difference in susceptibility rates was for PIPC in June 2014, and this was consistent at all duplicate isolate removal periods. At the 180-day duplicate isolate removal period, the rates for PIPC were 84.7% for the 6-month data collection period and 92.0% for the 12-month data collection period, indicating a difference of 7.3%. Similarly, the PIPC rates at the 30-day duplicate isolate removal period were 82.8% (6-month periods) and 89.9% (12-month periods), indicating a difference of 7.1%. The PIPC rates when all isolates were used were 78.4% (6-month periods) and 87.2% (12-month periods), with a difference of 8.8%.

Significant differences in susceptibility rates due to data collection periods were observed for PIPC, PIPC/TAZ, and CAZ, all of which were collected in December 2015 with a 30-day duplicate isolate removal period, with susceptibility rates for the 6-month collection period being higher than those for the 1-year collection period (*P\<*0.05). The susceptibility rates of PIPCs collected in January 2014 using all isolates also showed significant differences in susceptibility rates between different data collection periods (*P\<*0.05).

In January 2014, the *P*. *aeruginosa* susceptibility rates were higher for all β-lactam antibiotics when the data collection period was set to 1 year compared with when it was set to 6 months. In addition, in December 2015, the *P*. *aeruginosa* susceptibility rates were lower for all β-lactam antibiotics when the data collection period was 1 year compared with when the data collection period was 6 months.

[Fig 4](#pone.0235059.g004){ref-type="fig"} shows susceptibility rate variations for *P*. *aeruginosa* to PIPC, PIPC/TAZ, and CZOP when the data collection intervals were set at 6 months and 12 months for the duplicate isolate removal periods of 180 days and 30 days, or when all the isolates were used.

![Effect of data collection period on *P*. *aeruginosa* susceptibility rates to piperacillin, piperacillin/tazobactam, and ceftazidime.](pone.0235059.g004){#pone.0235059.g004}

When the data collection period was 6 months, greater than 10% increases were noted in susceptibility rates for PIPC, PIPC/TAZ, and CZOP in the second half of 2015, followed by a more than 5% decline, with no further variations. Meanwhile, when the data collection period was 12 months, an approximately 5% increase in the susceptibility rate in the second half of 2015, nor any subsequent declines, were observed ([Fig 4](#pone.0235059.g004){ref-type="fig"}).

Please refer to the supporting information for detailed data about changes in the *P*. *aeruginosa* susceptibility rates to β-lactam antibiotics according to the data collection periods ([S1 Fig](#pone.0235059.s001){ref-type="supplementary-material"}).

The *P*. *aeruginosa* susceptibility rates to non-β-lactam antibiotics did not show regular changes due to the data collection period. The antimicrobial agent with the largest change in susceptibility rate due to differences in the data collection period was GM, which was calculated in June 2014, with the duplicate isolate removal period set to 30 days, with an 8.2% difference. In June 2014, susceptibility rates for all antimicrobial agents were higher when the data collection period was 1 year compared with when the data collection period was 6 months.

The *E*. *coli* susceptibility rates to β-lactam antibiotics did not show regular changes due to the data collection period. The antimicrobial agent with the largest change in susceptibility rate due to differences in the data collection period was CFPN, which was calculated in June 2014 using all isolates (a 7.1% difference).

The *E*. *coli* susceptibility rates to non-β-lactam antibiotics did not show regular changes due to the data collection period. The antimicrobial agent with the largest change in susceptibility rate due to differences in the data collection period was LVFX, which was calculated in December 2015 using all isolates (a 4.3% difference).

The *K*. *pneumoniae* susceptibility rates to β-lactam antibiotics did not show regular changes due to the data collection period. The antimicrobial agent with the largest change in susceptibility rate due to differences in the data collection period was ABPC/SBT, which was calculated in December 2014 using all isolates (a 6.5% difference).

The *K*. *pneumoniae* susceptibility to non-β-lactam antibiotics did not show regular changes due to the data collection period. The antimicrobial agent with the largest change in susceptibility rate due to differences in the data collection period was MINO, which was calculated in December 2014 using all isolates (a 5.7% difference).

Influence of hospital relocation on patient dynamics {#sec021}
----------------------------------------------------

[Table 7](#pone.0235059.t007){ref-type="table"} shows the number of target patients, the number of patients who visited the pre-relocation hospital and underwent susceptibility testing, and the proportion of those patients in the target patients. All data was calculated every six months for each bacterial type.

10.1371/journal.pone.0235059.t007

###### The number of target patients every 6 months.

![](pone.0235059.t007){#pone.0235059.t007g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
                patients who visited the pre-relocation hospital\   percentage of patients who visit old location (%)                                      
                / target patients                                                                                                                          
  ------------- --------------------------------------------------- --------------------------------------------------- ---------- ---------- ------ ----- -----
  2014          first half                                          \- / 106                                            \- / 313   \- / 100   \-     \-    \-

  second half   \- / 142                                            \- / 353                                            \- / 132   \-         \-     \-    

  2015          first half                                          \- / 102                                            \- / 346   \- / 104   \-     \-    \-

  second half   21 / 165                                            43 / 369                                            10 / 130   12.7       11.7   7.7   

  2016          first half                                          10 / 112                                            22 / 431   2 / 133    8.9    5.1   1.5

  second half   6 / 184                                             15 / 462                                            2 / 179    3.3        3.2    1.1   

  2017          first half                                          7 / 164                                             20 / 422   5 / 176    4.3    4.7   2.8

  second half   7 / 178                                             20 / 407                                            5 / 183    3.9        4.9    2.7   

  2018          first half                                          7 / 133                                             12 / 418   3 / 158    5.3    2.9   1.9

  second half   4 / 172                                             8 / 429                                             2 / 213    2.3        1.9    0.9   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

For all bacterial species, for one year after hospital relocation patients who had consulted the pre-relocation hospital accounted for approximately 10% of all target patients. Afterwards, the proportion of patients who visited the pre-relocation hospital decreased sharply, settling under 3% in late 2018.

Discussion {#sec022}
==========

Effect of duplicate isolate removal periods {#sec023}
-------------------------------------------

First, this study showed that for any bacterial species, the longer the duplicate isolate removal period, the fewer isolates are available and the higher the calculated susceptibility rate. This finding is consistent with previous reports \[[@pone.0235059.ref005], [@pone.0235059.ref006]\].

When calculating the *P*. *aeruginosa* susceptibility rates using 1 year of data, setting the duplicate isolate removal period to 30 days reduced the available target strain by approximately 30% compared with using all the strains. When the duplicate isolate removal period was 365 days (that is, when only the first strain of the same patient was used), the available strains decreased by about 40%. In the cases of *E*. *coli* and *K*. *pneumoniae*, when the duplicate isolate removal period was 365 days, the available target strains were reduced by approximately 30% and 20%, respectively, compared with when all the strains were used.

A decrease of between 20% and 40% in target isolates resulting from setting duplicate isolate removal periods is a major problem when facilities have little antimicrobial susceptibility test data. This is also true for bacterial species with a small number of cases. To acquire adequate data in such situations, the data collection period could be extended, or data could be compiled with data from other institutions.

However, when either of these approaches are used (i.e., extending the data collection period or pooling data from other institutions), a question arises about whether the resulting antibiogram accurately reflects the true situation at the respective facility.

Next, we showed that the susceptibility rates of *P*. *aeruginosa* to β-lactam antibiotics were significantly higher when the duplicate isolate removal periods were set at 180 and 365 days, respectively, than when whole strains were used. The *P*. *aeruginosa* susceptibility rates to β-lactam antibiotics increased by 1.4%--10.7% when the duplicate isolate removal period was 365 days when compared with using all the strains.

The susceptibility rates for other combinations of bacterial species and antimicrobial agents did not show a significant increase as seen with *P*. *aeruginosa* to β-lactam antibiotics when increasing the duplicate isolate removal period. However, increasing the duplicate isolate removal period caused the susceptibility rate to increase within a range of several per cent.

It should be noted that susceptibility rates may change due to changes in the duplicate isolate removal period. As found in the comparison of coefficients of variation, the duplicate isolate removal period has a greater impact on the susceptibility rate in *P*. *aeruginosa* than in *E*. *coli* and *K*. *pneumoniae*.

Antibiograms are used to assess susceptibility rates, as an aid in selecting antimicrobials in empiric therapy, in monitoring resistance trends over time within an institution, in comparing susceptibility rates across institutions, and in tracking resistance trends \[[@pone.0235059.ref009]\]. Thus, the clinician should be fully aware that the antibiogram susceptibility results for any pathogen and antimicrobials, particularly *P*. *aeruginosa* and β-lactam antibiotics, may vary based on the duplicate isolate removal periods. Other antimicrobial agents in *P*. *aeruginosa*, and with respect to antibiograms of *E*. *coli* and *K*. *pneumoniae*, do not appear to be of such concern.

Impact of the data accumulation period {#sec024}
--------------------------------------

In this study, it was demonstrated that when calculating the susceptibility rate every 6 months, it differs by approximately 4%--8% depending on whether the data collection period is set to 6 months or 1 year. Medical personnel using antibiograms should be aware of this fact.

As demonstrated in [Table 7](#pone.0235059.t007){ref-type="table"}, the patient population changed drastically both prior to and after relocation of the Sakai City Hospital Center, which may reflect changes in the bacterial flora within and outside the hospital environment. Therefore, susceptibility trends observed in [Fig 4](#pone.0235059.g004){ref-type="fig"} with a data collection period of 6 months, can be interpreted as follows.

In the first half of 2015, the *P*. *aeruginosa* strains circulating within and outside the pre-relocation hospital were susceptible to PIPC with values ranging from 81%--91%, and for PIPC/TAZ this ranged from 85%--95%, and for CAZ this ranged from 84%--94%. On the other hand, it is estimated that the *P*. *aeruginosa* strains circulating at the new relocation site had good susceptibility to both antimicrobials since the majority of the patients were replaced by new residents at the new site. Immediately after the move in July 2015, PIPC showed susceptibility rates of 93%--99%, while for PIPC/TAZ, this was 95%--100%, and for CAZ, this was 94%--100%. Afterwards, it is expected that hospital staff and patients from the old location site would have introduced *P*. *aeruginosa* from the pre-relocation hospital flora to the local bacteria at the new site, resulting in gene mixing and exchange of drug resistance genes, eventually leading to a new susceptibility profile \[[@pone.0235059.ref010], [@pone.0235059.ref011]\].

Thus, it is reasonable to suggest that the susceptibility trends observed in [Fig 1](#pone.0235059.g001){ref-type="fig"} for a data collection period of 6 months reflect the changes in bacterial flora and subsequent changes due to hospital relocation. However, in the case of the 1-year data collection period, since the data from the first and second halves of 2015 were shown as data for the second half of 2015, a sharp rise in susceptibility rate was not observed. We were also unable to observe any floral changes resulting from hospital relocation and the subsequent transition.

As such, even if a significant change occurs in antimicrobial susceptibility during the analysis period, a large change in susceptibility may be obscured by calculating susceptibility rate combining data of pre- and post- change. Also, since bacteria such as *P*. *aeruginosa*, which do not require special nutrients for growth, easily multiply, have a variety of resistance mechanisms, and easily acquire resistance, antimicrobial susceptibility rates may change drastically over a few months. Therefore, a significant change in susceptibility rate may be missed if the data accumulation period is not as long as possible. This point should always be noted when evaluating trends in susceptibility rates of antimicrobial drugs. The CLSI guidelines recommend updating antibiograms "at least annually" \[[@pone.0235059.ref003]\]. However, we believe they should be updated within the shortest time period that is practically possible, taking into account restrictions such as numbers of specimen.

Conclusions {#sec025}
===========

In this study we have clearly demonstrated how antibiograms are influenced by various parameters including duplicate isolate removal periods and data collection periods. Furthermore, our data suggests that changes in antimicrobial susceptibility rates may be missed depending on the data accumulation period and timepoints used during antibiogram preparation.

In addition to the personnel involved in creating the antibiograms, the medical personnel involved in treating infectious diseases, who also interpret such antibiograms, need to be well aware of the extent to which these parameters influence antibiograms. It is also important to unify parameter values when comparing antibiograms from multiple facilities, and the parameter values used to create the antibiograms should be clearly indicated.

Ideally, medical professionals involved in treatment of infectious diseases should select antimicrobial agents based on their experience in daily clinical care and use antibiograms based on various parameter values. To do so, a system such as Chans, which allows the operator to browse and set various parameter values and conditions to rapidly calculate antimicrobial susceptibility or resistance rates, is recommended.

Supporting information {#sec026}
======================

###### Changes in the *P*. *aeruginosa* susceptibility rates to β-lactam antibiotics according to the data collection periods.

(TIF)

###### 

Click here for additional data file.

###### Difference in susceptible rate when the duplicate isolate removal periods were set at 365 days, 180 days, and 30 days, compared with when all isolates were used.

(XLSX)

###### 

Click here for additional data file.
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Reviewer 1:

Thank you for your helpful suggestions. I appreciate your time and effort spending for our manuscript. I have all of your suggestions into my revision.

1\. Pseudomonas aeruginosa are notorious for their ability in the upregulation of intrinsic resistance mechanisms, especially in the presence of antibiotic use. Inclusion of another organism, e.g. Enterobacteriaceae, may provide a more complete picture of how varying parameters affect susceptibility rates in antibiogram.

→ We added Escherichia coli and Klebsiella pneumoniae to target bacteria. And we recreated data and rewrite manuscript. Although the final conclusions have not changed significantly, it has become clear that the magnitude of influence of parameters differs according to the bacterial species.

2\. Also, only beta-lactam antibiotics were included in this study, thus it will be interesting to see if similar changes of susceptibility rate are observed for the other classes of antibiotics, e.g. fluoroquinolones, aminoglycosides.

→ We added 20 more antibiotics to target antibiotics, including 2 fluoroquinolones, 3 aminoglycosides, and others. And we recreated data for 29 target antibiotics in 9 groups, and rewrite manuscript.

Minor issues:

1\. Table 1 does not add much information. The total number of isolates can be put into table 2 in an additional column.

→ As a new Table 1 was inserted to the manuscript, Table 1 and Table 2 were renamed to Table 2 and Table 3, respectively. Table 2 and Table3 had become complicated because of the increase in number of target bacterial species and target antibiotics. Therefore, we did not integrate Table 2 and Table 3 into one table.

2\. Dripenem should be spelt doripenem.

→ I replaced "dripenem" with "doripenem".

3\. p. 13 Line 222 cefzoplan should be spelt cefozopran

→ I replaced "cefzopran" with "cefozopran".

In "Revised Manuscript with Track Changes", deleted parts are shown in strikethrough and red text, and added parts are shown in blue text. Please understand that corrections to minor grammatical or calculation errors in the manuscript that do not affect the conclusion are not shown in red or blue text.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address all concerns by both reviewers. In particular, the rank order may appear statistifcally or analytically significant but have doubtful meaning in real life. It will be best if the authors can come up with an alternative and more meaningful way to look at the changes in the antibiogram.

We would appreciate receiving your revised manuscript by May 31 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.
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Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.
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We look forward to receiving your revised manuscript.

Kind regards,
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Hatsuda et al attempted to demonstrate the impact of data collection/analysis protocols on antibiograms for Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, through an analysis of 5 years' worth of susceptibility data from a regional centre, including relocation to a different primary medical care area in Jul 2015. While I agree with the authors' conclusion that antibiogram can be influenced by various parameter change and that personnel involved in creating and using the antibiogram should be aware of these limitations, the method of data analysis and presentations suffered much deficiencies in the current manuscript.

For example,

1\. The statistical significance of the susceptibility rate difference of the various 'dupulicate isolate removal periods' should be calculated instead of the absolute change in %.

2\. The ranking order of antibiotic susceptibility rate has little clinical or interpretation significance and can be omitted entirely to simplify table 3.

3\. Subgroup analysis could include comparisons between Pseudomonas aeruginosa and the Enterobacteriaceae, as well as between various antibiotic groups. These further analyses could reveal that Enterobacteriaceae susceptibility data are less affected by the change in period of deduplications for beta-lactam antibiotics, and aminoglycoside group antibiotics are not significantly affected by the deduplication periods etc. Such observations could then be followed by authors' postulation of the mechanisms, e.g. difference in antimicrobial resistance mechanisms in Pseudomonas aeruginosa and Enterobacteriaceae or for various antibiotics, and that antibiograms are affected by how the data collection parameters were set.

Reviewer \#2: PONE-D-19-32239R1: Dr. Hatsuda et al report on their work in regard to varying the length of time of duplicate Gram-negative isolate removal in the creation of a single center antibiogram. The manuscript highlights important findings that persons using antibiograms need to be aware of when using antibiograms to select empiric coverage for typical Gram negative infections. The results section if very long due to the addition of the concept of ranking the order of susceptibilities. It is evident that the paper is improved from the original version and additional antimicrobials were added to the study results.

Major concern:

1\) It is not clear what impact the "rank order of antimicrobial susceptibility" has to a clinician. It seems academic and, while novel, perhaps, it is not clearly based in a clinical practice. For example, no clinician choses an antibiotic based on the highest or lowest susceptibility percentage. Typically, for any given pathogen, a drug is chosen for it's known activity, safety profile, susceptibility (as a "Yes" susceptible or "No" not susceptible) and hospital formulary/cost, availability. CLSI breakpoints, not "rank order of susceptibility," are used clinically with the many other factors noted. Therefore, unless the authors can cite a reference where this concept is used and/or describe a clinical usefulness, this reviewer suggests that all references to "rank order of susceptibility" be placed in supplemental sections and be removed from tables in regular manuscript. Would also remove reference to them from results sub-section. Again, although the rank order of susceptibility may change based on the duplicate isolate removal times, this is not necessarily helpful information to the clinician.

Minor concerns:

Table 1: CTX is given as the abbreviation for two cephalosporins, this should be corrected before publication.

Throughout the entire manuscript (and namely in tables and figures), again, DORIPENEM and CEFOZOPRAN need spelling corrected. This is noted in Table 1 with doripenem, FIGURE 1 for both, and also in Table title text.

Line 390: This reviewer would avoid using terms such as "a few percent" as it is not customary reporting.

Discussion: Somewhere in the discussion the authors should add some reference to the fact that antibiograms are used for empiric selection of antimicrobials pending full culture results, therefore, the clinician should fully grasp that the antibiogram susceptibility results for any pathogen and antibiotic may vary, even tremendously, based on the interval of time (duration) for which duplicate isolates are removed from the calculation/percentages.

Line 461: Would remove term "settle down" and chose alternate wording.

Line 499: Last word, "required." would replace with "recommended."
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Thank you for your helpful suggestions. I appreciate the time and effort you spent reviewing our manuscript. I have taken all of your suggestions into account in my revision.

Reviewer 1:

1\. The statistical significance of the susceptibility rate difference of the various 'duplicate isolate removal periods' should be calculated instead of the absolute change in %.

→ We used the chi-square test to assess for associations between susceptibility rate and the duplicate isolate removal periods. In addition, differences in sensibility rates between the long and short data collection periods were also tested using the chi-square test. (Line 129)

2\. The ranking order of antibiotic susceptibility rate has little clinical or interpretation significance and can be omitted entirely to simplify table 3.

→ We agree with your assessment. We abandoned the idea of ranking order and have removed Table 3.

3\. Subgroup analysis could include comparisons between Pseudomonas aeruginosa and the Enterobacteriaceae, as well as between various antibiotic groups. These further analyses could reveal that Enterobacteriaceae susceptibility data are less affected by the change in period of deduplications for beta-lactam antibiotics, and aminoglycoside group antibiotics are not significantly affected by the deduplication periods etc.

→ We showed that the duplicate isolate removal periods significantly affected the susceptibility rate only in Pseudomonas aeruginosa β-lactams. We also compared differences in susceptibility rates across data collection periods using coefficients of variation to highlight differences between β-lactams and other antimicrobials in P. aeruginosa, and between P. aeruginosa and two other bacterial species.

Reviewer 2:

1\. It is not clear what impact the "rank order of antimicrobial susceptibility" has to a clinician.

→ We agree with your assessment. We abandoned the idea of ranking order of antimicrobial susceptibility and have removed Table 3.

2\. Table 1: CTX is given as the abbreviation for two cephalosporins, this should be corrected before publication. Throughout the entire manuscript (and namely in tables and figures), again, DORIPENEM and CEFOZOPRAN need spelling corrected. This is noted in Table 1 with doripenem, FIGURE 1 for both, and also in Table title text.

→ I apologize for my carelessness. I have corrected Table 1 and other relevant sections in the manuscript.

3\. Line 390: This reviewer would avoid using terms such as "a few percent" as it is not customary reporting..

→ I corrected the phrase \"at a few percent\" to \"under 3%\" in the relevant sections. (Line 295)

4\. Discussion: Somewhere in the discussion the authors should add some reference to the fact that antibiograms are used for empiric selection of antimicrobials pending full culture results, therefore, the clinician should fully grasp that the antibiogram susceptibility results for any pathogen and antibiotic may vary, even tremendously, based on the interval of time (duration) for which duplicate isolates are removed from the calculation/percentages.

→ We have inserted the appropriate text and the reference you pointed to in the "Effect of duplicate isolate removal periods" section of the "Discussion." (Line 331)

5\. Line 461: Would remove term "settle down" and chose alternate wording.

→ I have corrected the phrase \"the emergence of new susceptibility profiles, which would eventually settle down\" to \"eventually leading to a new susceptibility profile\" in the relevant section. (Line 357)

6\. Line 499: Last word, "required." would replace with "recommended.".

→ I have corrected the phrase \"required\" to \"recommended\" in the relevant section. (Line 390)

In "Revised Manuscript with Track Changes," deleted parts are shown in strikethrough and red text. Text that has been added is shown in blue text. Please consider that minor grammatical corrections to the manuscript that do not affect the conclusion are not shown in red or blue text.
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PLOS ONE

Dear Dr. HATSUDA,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewers\' comments in the last revision have been addressed satisfactorily. However, there remains a few typos/ language issues that could be resolved easily. They are as follows:

1\. L86-87: Gram stain is named after its inventor, and thus \"Gram\" should always be spelt with a capital \"G\".

2\. L85-86: It is not necessary to introduce the abbreviated forms of bacterial names as this is the convention in biomedical literature.

3\. L92 & table 1: In biomedical literature, colistin should be classified as a polymyxin or a nonribosomal peptide.

4\. L116: Consider changing to \"As it is possible that isolates from the same patient among long-term in-patients may undergo \...\"

5\. L119: \"\... to prevent results from being affected \...\"

6\. L147: space missing from E. coli

Please submit your revised manuscript by Jul 19 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Herman Tse

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0235059.r006
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Dear Dr. Herman Tse,

Thank you for your helpful suggestions. I appreciate the time and effort you spent reviewing our manuscript. We have taken all of your suggestions into account in my revision. I hope that our edits and the responses we provide below satisfactorily address all the issues and concerns you have noted.

1\. L86-87: Gram stain is named after its inventor, and thus \"Gram\" should always be spelt with a capital \"G\".

→ In accordance with your advice, we have changed "gram-negative" to "Gram-negative". (Line 83, 84)

2\. L85-86: It is not necessary to introduce the abbreviated forms of bacterial names as this is the convention in biomedical literature.

→ We thank you for this comment. Accordingly, we have deleted the abbreviated forms. (Line 85, 86)

3\. L92 & table 1: In biomedical literature, colistin should be classified as a polymyxin or a nonribosomal peptide.

→ We appreciate your comment on this point. Accordingly, we have changed colistin classification to "polymyxins". (Line 92, Table 1)

4\. L116: Consider changing to \"As it is possible that isolates from the same patient among long-term in-patients may undergo \...\"

→ Thank you for your suggestion. We have changed the sentence you pointed out as your suggestion. (Line 115)

5\. L119: \"\... to prevent results from being affected \...\"

→ Thank you for your advice. We have changed the sentence by adding "from", which I forgot to add. (Line 118)

6\. L147: space missing from E. coli

→ Thank you for your advice. The error you pointed out has been corrected. (Line 146)

In "Revised Manuscript with Track Changes," deleted parts are shown in strikethrough and red text. Text that has been added is shown in blue text.

Again, thank you for giving us the opportunity to strengthen our manuscript with your valuable comments. We have worked to incorporate your feedback and hope that these revisions persuade you to accept our submission.
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Dear Dr. HATSUDA,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Herman Tse

Academic Editor

PLOS ONE
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Influence of analysis conditions for antimicrobial susceptibility test data on susceptibility rates

Dear Dr. HATSUDA:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Herman Tse

Academic Editor

PLOS ONE
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